GEORGE J. MORROW - Corporate Board Profile

ALIGN TECHNOLOGY INC

Filing Date	Source Excerpt
2013-04-18	Mr. Morrow has served as a director of Align since February 2006. From February 2011 until January 2013, Mr. Morrow served as a consultant to Amgen Inc., a global biotechnology company. From 2003 until his retirement in February 2011, he was the executive vice president, global commercial operations at Amgen Inc., where he also served as executive vice president of worldwide sales and marketing between 2001 and 2003. From 1992 to 2001, Mr. Morrow held multiple leadership positions at GlaxoSmithKline Inc. and its subsidiaries, including president and chief executive officer of Glaxo Wellcome Inc. He is a member of the board of directors of Vical Incorporated, a company that researches and develops biopharmaceutical products and was a member of the board of directors of Human Genome Sciences, Inc., a biopharmaceutical discovery and development company, from March 2011 until its acquisition in August 2012 by GlaxoSmithKline plc. Mr. Morrow holds a B.S. in Chemistry from Southampton College, Long Island University, an M.S. in Biochemistry from Bryn Mawr College and an M.B.A. from Duke University.
2014-04-04	Mr. Morrow holds a B.S. in Chemistry from Southampton College, Long Island University, an M.S. in Biochemistry from Bryn Mawr College and an M.B.A. from Duke University. His experience is in biotechnology and pharmaceuticals.
2015-04-01	Mr. Morrow holds a B.S. in Chemistry from Southampton College, Long Island University, an M.S. in Biochemistry from Bryn Mawr College and an M.B.A. from Duke University.
2016-03-17	Mr. Morrow has served as a director of Align since February 2006. From February 2011 until January 2013, Mr. Morrow served as a consultant to Amgen Inc., a global biotechnology company. From 2003 until his retirement in February 2011, he was the Executive Vice President, Global Commercial Operations at Amgen Inc., where he also served as Executive Vice President of Worldwide Sales and Marketing between 2001 and 2003. From 1992 to 2001, Mr. Morrow held multiple leadership positions at GlaxoSmithKline Inc. and its subsidiaries, including President and Chief Executive Officer of Glaxo Wellcome Inc. He is a member of the board of directors of Vical Incorporated, a company that researches and develops biopharmaceutical products, Safeway Inc., a food and drug retailer and was a member of the board of directors of Human Genome Sciences, Inc., a biopharmaceutical discovery and development company, from March 2011 until its acquisition in August 2012 by GlaxoSmithKline plc. Mr. Morrow holds a B.S. in Chemistry from Southampton College, Long Island University, an M.S. in Biochemistry from Bryn Mawr College and an M.B.A. from Duke University.
2016-04-07	Mr. Morrow holds a B.S. in Chemistry from Southampton College, Long Island University, an M.S. in Biochemistry from Bryn Mawr College and an M.B.A. from Duke University.
2017-04-06	Mr. Morrow holds a B.S. in Chemistry from Southampton College, Long Island University, an M.S. in Biochemistry from Bryn Mawr College and an M.B.A. from Duke University. Mr. Morrow brings to our Board considerable business experience in the medical technology industry.
2018-04-05	Mr. Morrow holds a B.S. in Chemistry from Southampton College, Long Island University, an M.S. in Biochemistry from Bryn Mawr College and an M.B.A. from Duke University. Mr. Morrow has served as a director of Align since February 2006. From February 2011 until January 2013, Mr. Morrow served as a consultant to Amgen Inc., a global biotechnology company.
2019-04-04	Mr. Morrow holds a B.S. in Chemistry from Southampton College, Long Island University, an M.S. in Biochemistry from Bryn Mawr College and an M.B.A. from Duke University. Mr. Morrow has recent front-line exposure to many of the issues facing public companies today, particularly on the operational, regulatory, financial and corporate governance fronts.
2020-04-06	Mr. Morrow has served as a director of Align since February 2006. From February 2011 until January 2013, Mr. Morrow served as a consultant to Amgen Inc., a global biotechnology company. From 2003 until his retirement in February 2011, he was the Executive Vice President, Global Commercial Operations at Amgen Inc., where he also served as Executive Vice President of Worldwide Sales and Marketing between 2001 and 2003. From 1992 to 2001, Mr. Morrow held multiple leadership positions at GlaxoSmithKline Inc. and its subsidiaries, including President and Chief Executive Officer of Glaxo Wellcome Inc. He is a member of the board of directors of Neurocrine Biosciences, a biotechnology company focused on neurologic, psychiatric and endocrine related disorders. He was previously on the board of directors of Vical Incorporated, a company that researches and develops biopharmaceutical products from 2013 to 2019. He was on the board of Safeway Inc., a food and drug retailer from May 2013 until February 2015. From April 2015 to June 2018, he was also on the board of Otonomy, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear. Mr. Morrow holds a B.S. in Chemistry from Southampton College, Long Island University, an M.S. in Biochemistry from Bryn Mawr College and an M.B.A. from Duke University.
2021-04-07	George J. Morrow Former EVP & Global Commercial Operations Amgen, Inc. Skills and Qualifications: Significant sales, marketing and operational global ownership roles with large publicly traded medical and healthcare technology companies Extensive background in medical device regulatory and compliance, financial, and corporate governance.
2022-04-05	George J. Morrow, 70, served as the Executive Vice President, Global Commercial Operations at Amgen Inc... Mr. Morrow earned an M.B.A. from Duke University, an M.S. degree in Biochemistry from Bryn Mawr College and a B.S. degree in Chemistry from Southampton College.
2023-04-05	George J. Morrow, 71, served as the Executive Vice President, Global Commercial Operations (2003-2011) and Executive Vice President of Worldwide Sales and Marketing (2001-2003) at Amgen Inc., a global biotechnology company. From 1992 to 2001, Mr. Morrow held multiple leadership positions at GlaxoSmithKline Inc. and its subsidiaries, including President and Chief Executive Officer of Glaxo Wellcome Inc. Mr. Morrow earned an M.B.A. from Duke University, an M.S. degree in Biochemistry from Bryn Mawr College and a B.S. degree in Chemistry from Southampton College, Long Island University.
2024-04-09	Education: B.S. in Chemistry from Southampton College, Long Island University; M.B.A. from Duke University; M.S. in Biochemistry from Bryn Mawr College
2025-04-08	Executive Vice President, Global Commercial Operations, Amgen Inc.; B.S. in Chemistry; M.B.A. from Duke University; M.S. in Biochemistry.

NEUROCRINE BIOSCIENCES INC

Filing Date	Source Excerpt
2016-05-02	The Company 27s Compensation Committee consists of directors Richard F. Pops, George J. Morrow, and Joseph Mollica, Ph.D. ... 2015 Director Compensation ... George J. Morrow ... $33,333 Fees Earned or Paid in Cash ... $1,038,800 Option Awards ... $1,072,133 Total
2017-04-21	George J. Morrow has served on the Board of Directors since October 2015. He is a member of the Compensation Committee. Director Compensation Table shows total compensation of $467,200 for 2016.
2018-04-04	The nomination of George J. Morrow for election to the Companys Board of Directors is based on his extensive commercialization experience at Amgen, his broad executive experience at GlaxoSmithKline Inc., and his years of experience in corporate governance as a board member of several publicly traded companies. Mr. Morrows board, leadership experience and commercialization expertise prove valuable strategic insights to the Board of Directors. The Companys Compensation Committee consists of directors Richard F. Pops, George J. Morrow and Corinne H. Nevinny. The Companys Nominating/Corporate Governance Committee consists of directors Stephen A. Sherwin, M.D., George J. Morrow and Alfred W. Sandrock, Jr. M.D., Ph.D., all of whom are independent directors as defined by Nasdaq Stock Market Rule 5605(a)(2). The following table sets forth the compensation paid by the Company for the fiscal year ended December 31, 2017 to the directors of the Company named below: George J. Morrow: Fees Earned or Paid in Cash $62,000, Option Awards $442,950, Total $504,950.
2019-04-17	The Company 2018 compensation for the Company 2018 to the directors of the Company named below: George J. Morrow 75,000 655,250 730,250
2020-04-09	George J. Morrow has served on the Board of Directors since October 2015. ... Mr. Morrow currently serves on the board of directors of Align Technology, Inc., a global medical device company. ... Mr. Morrow holds a B.S. in chemistry from Southampton College, Long Island University, an M.S. in biochemistry from Bryn Mawr College and an M.B.A. from Duke University.
2021-04-09	George J. Morrow has served on the Board of Directors since October 2015. The Companys Compensation Committee consists of directors George J. Morrow, Richard F. Pops and Shalini Sharp. The Nominating/Corporate Governance Committee consists of directors Stephen A. Sherwin, M.D., George J. Morrow and Leslie V. Norwalk. For 2020, directors who are not employees of the Company earned a $55,000 annual cash retainer. Each other director who was a member of the Compensation Committee earned an additional annual cash retainer of $12,000, and each other director who was a member of the Nominating/Corporate Governance Committee earned an additional annual cash retainer of $5,000. Additionally, for 2020, each non-employee director received a grant of a nonstatutory stock option to purchase 6,018 shares of the Companys common stock, representing an approximate value of $400,000 on the date of the 2020 Annual Meeting of Stockholders. The following table sets forth the compensation earned for the fiscal year ended December 31, 2020 by the directors of the Company named below: George J. Morrow Fees Earned or Paid in Cash $75,734 Option Awards $400,030 Total $475,764.
2022-04-07	George J. Morrow has served on the Board of Directors since October 2015. ... The Company’s Compensation Committee consists of directors George J. Morrow, Richard F. Pops, and Shalini Sharp, with Mr. Pops serving as the Compensation Committee Chair. ... The Company’s Nominating/Corporate Governance Committee consists of directors Stephen A. Sherwin, M.D., Johanna Mercier, George J. Morrow, and Leslie V. Norwalk, with Ms. Norwalk serving as the Nominating/Corporate Governance Committee Chair. ... For 2021, directors who are not employees of the Company earned a $60,000 annual cash retainer. ... The following table sets forth the compensation earned for the fiscal year ended December 31, 2021 by the directors of the Company named below: George J. Morrow $79,500 fees earned in cash and $400,003 option awards totaling $479,503.
2023-04-05	George J. Morrow has served on the Board of Directors since October 2015. Mr. Morrow served as Executive Vice President, Global Commercial Operations at Amgen Inc., a global biotechnology company, from 2003 until his retirement in 2011. He joined Amgen in 2001 as Executive Vice President, Worldwide Sales and Marketing. His responsibilities included oversight of all commercial functions for Amgen’s broad spectrum of products in more than 50 countries worldwide, and the introduction of multiple new products into global markets. From 1992 to 2001, Mr. Morrow held executive management and commercial positions within several subsidiaries of Glaxo Wellcome, including Group Vice President for Commercial Operations (U.S.), Managing Director (U.K.), and most recently as President and Chief Executive Officer of Glaxo Wellcome, Inc. (U.S.). Mr. Morrow currently serves on the Board of Directors of Align Technology, Inc., a global medical device company. He has previously served on the boards of Vical, Inc., Otonomy, Inc., Glaxo Wellcome, Inc., Human Genome Sciences, Inc., Safeway, Inc., National Commerce Bank, the John Hopkins School of Public Health, and the Duke University Fuqua School of Business. Mr. Morrow holds a B.S. in Chemistry from Southampton College, Long Island University, an M.S. in Biochemistry from Bryn Mawr College and an M.B.A. from Duke University. The Company’s Nominating/Corporate Governance Committee consists of directors Stephen A. Sherwin, M.D., Johanna Mercier, George J. Morrow, and Leslie V. Norwalk, with Ms. Norwalk serving as the Nominating/Corporate Governance Committee Chair. Dr. Sherwin, Ms. Mercier, Mr. Morrow, and Ms. Norwalk are all “independent directors” as defined by Nasdaq Stock Market Rule 5605(a)(2).
2024-04-10	George J. Morrow has served on the Board of Directors since October 2015. ... Mr. Morrow currently serves on the Board of Directors of Align Technology, Inc., a publicly traded global medical device company. ... The Company’s Compensation Committee consists of directors George J. Morrow, Richard F. Pops, and Shalini Sharp, with Mr. Pops serving as the Compensation Committee Chair. ... During 2023, the Company’s Nominating / Corporate Governance Committee consisted of directors Johanna Mercier, George J. Morrow, and Leslie V. Norwalk, and Stephen A. Sherwin, M.D., with Ms. Norwalk serving as the Nominating / Corporate Governance Committee Chair. ... The table below provides membership information for each of the committees of the Board during 2023. ... George J. Morrow is a member of the Compensation Committee and the Nominating / Corporate Governance Committee. ... For fiscal 2023, directors who are not employees of the Company earned a $60,000 annual cash retainer. ... For fiscal 2023, on the date of the 2023 Annual Meeting of Stockholders, each continuing non-employee director received an annual equity award with an approximate grant date value of $400,000. ... The following table sets forth the compensation earned for the fiscal year ended December 31, 2023 by the directors of the Company named below: ... George J. Morrow $79,500 cash fees, $400,039 stock awards, total $479,539.